Experimental siRNA therapy lowers HBsAg levels in people with hepatitis B
Entecavir and tenofovir work well for people with drug-resistant hepatitis B virus
One million people with hepatitis C in the US at high priority for treatment
Many hepatitis C patients with cirrhosis or advanced fibrosis face liver failure and liver cancer
Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis
Sofosbuvir/ledipasvir with ribavirin cures most people with hepatitis C recurrence after liver transplantation
Sofosbuvir + simeprevir shows good results for hepatitis C in real-world use
DAAs show good cure rates and liver function improvement for transplant recipients with recurrent HCV
AbbVie 3D regimen cures recurrent HCV in most liver transplant recipients without cirrhosis
Tenofovir continues to suppress hepatitis B virus for eight years
Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C
AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection
Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients
Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients
Merck's grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection
Sofosbuvir/ledipasvir and AbbVie 2D regimen cure most people with HCV genotype 4
Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis
